Posted innews Psychiatry
ANK3-Guided Liafensine Shows Clinically Meaningful Benefit in Treatment‑Resistant Depression: Results of the ENLIGHTEN Trial
In ENLIGHTEN, a biomarker-guided randomized trial, ANK3-positive patients with treatment‑resistant depression randomized to liafensine achieved larger MADRS improvements than placebo (mean difference −4.4; 95% CI −7.6 to −1.3; P = .006), with acceptable tolerability.